{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:15:34Z","timestamp":1790702134416,"version":"4.1.0"},"reference-count":13,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.jaad.2017.02.049","type":"journal-article","created":{"date-parts":[[2017,4,5]],"date-time":"2017-04-05T15:02:24Z","timestamp":1491404544000},"page":"1054-1060.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":163,"title":["Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib"],"prefix":"10.1016","volume":"76","author":[{"given":"Brooke","family":"Rothstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deep","family":"Joshipura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ami","family":"Saraiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana","family":"Abdat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huda","family":"Ashkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1349-5279","authenticated-orcid":false,"given":"Yana","family":"Turkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaneeta","family":"Sheth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiu Chung","family":"Au","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"Kachuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Dumont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice B.","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Rosmarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"223","key":"10.1016\/j.jaad.2017.02.049_bib1","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007811","article-title":"CXCL10 is critical\u00a0for the progression and maintenance of depigmentation in a mouse model of vitiligo","volume":"6","author":"Rashighi","year":"2014","journal-title":"Sci Transl Med"},{"issue":"7","key":"10.1016\/j.jaad.2017.02.049_bib2","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/jid.2011.463","article-title":"A mouse model of vitiligo with focused epidermal depigmentation requires IFN-gamma for autoreactive CD8(+) T-cell accumulation in the skin","volume":"132","author":"Harris","year":"2012","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2017.02.049_bib3","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1146\/annurev.iy.07.040189.001045","article-title":"TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties","volume":"7","author":"Mosmann","year":"1989","journal-title":"Annu Rev Immunol"},{"issue":"6603","key":"10.1016\/j.jaad.2017.02.049_bib4","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/383787a0","article-title":"Functional diversity of helper T\u00a0lymphocytes","volume":"383","author":"Abbas","year":"1996","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.jaad.2017.02.049_bib5","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamadermatol.2015.1520","article-title":"Tofacitinib citrate for the treatment of vitiligo: a pathogenesis-directed therapy","volume":"151","author":"Craiglow","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2017.02.049_bib6","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jaad.2015.09.073","article-title":"Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA)","volume":"74","author":"Harris","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2017.02.049_bib7","unstructured":"Incyte. Investigator's Brochure (IB) INCB018424 Phosphate Cream. Report date April 10, 2015."},{"issue":"6","key":"10.1016\/j.jaad.2017.02.049_bib8","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/archderm.140.6.677","article-title":"Parametric modeling of narrowband UV-B phototherapy for vitiligo using a novel quantitative tool: the Vitiligo Area Scoring Index","volume":"140","author":"Hamzavi","year":"2004","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2017.02.049_bib9","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1600-0749.2006.00355.x","article-title":"The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force","volume":"20","author":"Taieb","year":"2007","journal-title":"Pigment Cell Res"},{"issue":"4","key":"10.1016\/j.jaad.2017.02.049_bib10","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/jamadermatol.2015.4445","article-title":"Topical ruxolitinib for the treatment of alopecia universalis","volume":"152","author":"Craiglow","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2017.02.049_bib11","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/bjd.13531","article-title":"Vitiligo assessment methods: vitiligo Area Scoring Index and Vitiligo European Task Force assessment","volume":"172","author":"Kohli","year":"2015","journal-title":"Br J Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2017.02.049_bib12","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1111\/j.1468-3083.2011.04215.x","article-title":"Acral lesions of vitiligo: why are they resistant to photochemotherapy?","volume":"26","author":"Esmat","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"10.1016\/j.jaad.2017.02.049_bib13","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1038\/jid.2015.335","article-title":"Transcriptional analysis of vitiligo skin reveals the alteration of WNT pathway: a promising target for repigmenting vitiligo patients","volume":"135","author":"Regazzetti","year":"2015","journal-title":"J Invest Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962217303018?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962217303018?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:42:53Z","timestamp":1759272173000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962217303018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S0190962217303018"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2017.02.049","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727490719.793531596","asserted-by":"object"}]},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2017.02.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}